logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

AACR 2020 – Does the dosing schedule of BRAF and MEK inhibitor combinations influence resistance?

The SWOG S1320 trial compared continuous and intermittent dosing of dabrafenib and trametinib in BRAF mutated melanoma